Regenics Launches Physician-Led GLP-1 Membership Program With Lower Medication Pricing
PRESS RELEASE Plentisoft
Aug. 12, 2026, 07:02 AM
Regenics has launched a new physician-led GLP-1 membership program that combines ongoing clinical oversight with lower medication pricing, offering semaglutide and tirzepatide alongside pharmaceutical-grade peptide and hormone optimization therapies, telemedicine access across the U.S., and complimentary medication delivery for eligible patients
Los Angeles, California, United States, August 12, 2026 — Regenics has launched a new physician-led GLP-1 membership program designed to expand access to medical weight loss care through ongoing clinical oversight and lower medication pricing. The new model replaces simplified bundled programs with a membership structure intended to support continuous supervision by the Regenics medical team. Under the program, patients receive unlimited access to their care team, along with ongoing prescription management, dose adjustments when appropriate, and refill coordination, with treatment plans tailored over time based on physiology, biomarker trends, and long-term health goals.
Membership starts at $39 for the first month and $79 per month thereafter, providing access to Regenics’ physician-led weight management framework. GLP-1 medications are billed separately based on prescribed dose, allowing pricing to change as treatment progresses in line with each patient’s clinical needs. Regenics offers semaglutide starting at $119 and tirzepatide starting at $199, with dosing determined by each patient’s metabolic response and physician guidance
The program builds on Regenics’ physician-led care model, which began at its Los Angeles-area clinic and later expanded through telemedicine to serve patients across the United States. Medical consultations at Regenics continue to be conducted by licensed medical professionals as the company broadens access to supervised GLP-1 treatment. “Biomarkers are the map. Your symptoms are the story. Our job is to bring those two things together,” said Phillip Marks, Head Nurse Practitioner at Regenics
In addition to GLP-1 care, members may also access physician-guided therapies such as pharmaceutical-grade peptide protocols, hormone optimization programs, metabolic support treatments, and advanced biomarker testing. The program’s weight management care is built around semaglutide and tirzepatide—FDA-approved active ingredients used in leading prescription weight-loss medications, including GLP-1 and dual GIP/GLP-1 therapies. Regenics now includes complimentary medication delivery so prescribed therapies can be shipped directly to patients’ homes without added shipping costs. “Patients want more than access to medication,” said Elise Easom, COO at Regenics. “They want physician guidance, ongoing support, and care that can adapt as their body and goals change. This membership model allows us to deliver that level of clinical support while improving affordability.”
Regenics said the membership launch reflects its broader view that medical weight loss should be managed as an ongoing clinical process rather than a one-time transaction. The company noted that more information on the GLP-1 membership structure, pricing, and eligibility criteria is available through its dedicated membership page at regenics.com/membership-landing
About Regenics
Regenics is a health and hormone optimization clinic built around physician-led, patient-centered care. The clinic helps individuals improve energy, metabolic function, weight control, sexual health, and long-term health through evidence-based medical protocols and personalized plans grounded in physiology and clinical data. What began as a local practice in Tarzana, California, has grown into one of the fastest-growing clinics in its field, expanding from in-person care in the Los Angeles area to secure telemedicine that now serves patients across the United States, with patient care remaining the constant behind that growth.
Contact Info: Name: David GaidukovychEmail: Send EmailOrganization: RegenicsWebsite: https://regenics.com/
Release ID: 89200426
If you encounter any issues, discrepancies, or concerns regarding the content provided in this press release, or if there is a need for a press release takedown, we urge you to notify us without delay at error@releasecontact.com (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our expert team will be available to promptly respond within 8 hours – ensuring swift resolution of identified issues or offering guidance on removal procedures. Delivering accurate and reliable information is fundamental to our mission.
Markets Insider and Business Insider Editorial Teams were not involved in the creation of this post.SHARE THIS POST
